Comparison · NCT01700192-sae
MK-8237 12 DU vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MK-8237 12 DU vs Placebo: serious adverse events. Trial comparisons, record NCT01700192-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01700192-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0148 | 0.00829 | 0.0263 | wilson | |
| Risk in group 2 | 0.00949 | 0.0046 | 0.0194 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00532 | -0.00659 | 0.0178 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.56 | 0.608 | 4 | log | |
| Odds ratio, group 1 over group 2 | 1.57 | 0.605 | 4.07 | log | |
| Number needed to harm, for one more participant with a serious adverse event on MK-8237 12 DU than on Placebo | 188 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MK-8237 12 DU | Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year. | 11 | 743 | EG000 |
| Group 2 | Placebo | Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year. | 7 | 738 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 54 weeks
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
- NCT number
- NCT01700192
- Phases
- PHASE3
- Conditions
- Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
- Interventions
MK-8237 tablets, Placebo tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets, Rescue Medication: Olopatadine ophthalmic drops, Rescue Medication: Mometasone furoate nasal spray
- Lead sponsor
- ALK-Abelló A/S
- Results first posted
- 2017-03-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01700192?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01700192-sae